Payment overview · 2025
General Payments
$197.17
12 reported records · 11 companies
Healthcare provider profile · identity verified
Julie M Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT CLOUD, MN · NPI 1235105388
Verified facts
What the public records show
CMS Open Payments records show Julie M Johnson, MD received $197.17 in general payments during 2025 across 12 reported records.
Astellas Pharma US Inc accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.16 | 22.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.29 | 12.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.51 | 9.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.66 | 9.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.12 | 8.2% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $15.55 | 7.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.86 | 7.5% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $13.94 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.63 | 6.9% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $9.64 | 4.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.81 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.17 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.16 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $9.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 187 | 53 |
| Omeprazole | Omeprazole | 171 | 48 |
| Gabapentin | Gabapentin | 158 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 36 |
| Lisinopril | Lisinopril | 127 | 38 |
| Losartan Potassium | Losartan Potassium | 125 | 36 |
| Tramadol Hcl | Tramadol Hcl | 106 | 27 |
| Atenolol | Atenolol | 96 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 26 |
| Simvastatin | Simvastatin | 82 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 23 |
| Eliquis | Apixaban | 73 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 22 |
| Alprazolam | Alprazolam | 65 | 15 |
| Alendronate Sodium | Alendronate Sodium | 64 | 19 |
| Metformin Hcl Er | Metformin Hcl | 63 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 19 |
| Metformin Hcl | Metformin Hcl | 55 | 15 |
| Furosemide | Furosemide | 53 | 16 |
| Promethazine Hcl | Promethazine Hcl | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 21 |
| Topiramate | Topiramate | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Spironolactone | Spironolactone | 47 | 11 |
| Bupropion Xl | Bupropion Hcl | 46 | 15 |
| Montelukast Sodium | Montelukast Sodium | 43 | 14 |
| Trazodone Hcl | Trazodone Hcl | 43 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 14 |
| Sertraline Hcl | Sertraline Hcl | 40 | 13 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Temazepam | Temazepam | 36 | suppressed |
| Estradiol | Estradiol | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Jardiance | Empagliflozin | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 12 |
| Prednisone | Prednisone | 19 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Baclofen | Baclofen | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.17 · 12 records | Astellas Pharma US Inc | Auvelity, BEXSERO, Cologuard Collection Kit, FREESTYLE LIBRE 3, ImmunoCAP, LEQVIO, LILETTA, NEXPLANON, SHINGRIX, VOQUEZNA, Veozah, ZURZUVAE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error